µ²ºc¦¡ |
|
Umeclidinium bromide
Vilanterol triphenylacetic acid-4-{(1R)-2-[(6-{2-[(2,6- dicholorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol (1:1)
|
UpToDate |
UpToDate ³sµ²
|
ÃIJz§@¥Î |
|
ANORO ELLIPTA §t¦³ umeclidinium »P vilanterol ¨âºØ¦¨¤À¡C Umeclidinium ¬O¤@ºØªø®Ä«¬§Ü¬r¿¸ÆPÃĪ«¡A³q±`¤SºÙ¬°§ÜÁxÆPÃĪ«¡C¨ä¹ï¬r¿¸ÆP¨üÅé¨È«¬ M1 ¦Ü M5 ªº¿Ë©M¤O¤jP¬Û¦P¡C¥»«~¦b®ð¹D¤¤²£¥ÍÃIJz§@¥Îªº¤è¦¡³z¹L§í¨î¥·Æ¦Ù¤Wªº M3 ±µ¨üÅé¡A±q¦Ó¾ÉP¤ä®ðºÞÂX±i¡C Vilanterol ¬O¤@ºØ LABA¡CÅé¥~¸ÕÅçÅã¥Ü¡Avilanterol ªº¥\¯à¿ï¾Ü©Ê»P salmeterol Ãþ¦ü¡C
|
¾AÀ³¯g |
|
ºC©Êªý¶ë©ÊªÍ¯f(COPD)±wªÌ¤§®ð¹Dªý¶ë¯gª¬ªººû«ùªvÀø¡C
|
¥Îªk¥Î¶q |
|
1. À³¥H¨C¤Ñ§l¤J ¤@¦¸ªº¤è¦¡§ëÃÄ¡A¥B¶È¥i¸g¤f§l¤J¡C 2. À³¨C¤Ñ©ó¬Û¦P®É¶¡§ëÃÄ¡C¨C24¤p®É¤£¥i¨Ï¥Î¶W¹L 1¦¸¡C 3. ¹ï¦Ñ¦~±wªÌ¡BµÇ¥\¯à¨ü·l±wªÌ©Î¤¤«×¨x¥\¯à¨ü·l±wªÌ¡A³£¤£¶·½Õ¾ã¾¯¶q¡C
|
ÃİʤO¾Ç |
|
§l¦¬¡G §l¤Jµ¹ÃĤ§«á¡A umeclidinium ¥Dn³£¬O±qªÍŦ§l¦¬¶i¤JÅ餺¡A¥u¦³·¥¤Ö¶q·|¸g¥Ñ¤fµÄ§l¦¬¡C«½Æ§l¤J§ë¤© ANORO ELLIPTA ¤§«á¡A¥i©ó 14 ¤Ñ¤º¹F¨ìéwª¬ºA¡A¥B»W¿n¶q³Ì°ª¬° 1.8 ¿¡C §l¤Jµ¹ÃĤ§«á¡Avilanterol ¥Dn³£¬O±qªÍŦ§l¦¬¶i¤JÅ餺¡A¥u¦³·¥·L¶q·|¸g¥Ñ¤fµÄ§l¦¬¡C«½Æ§l¤J§ë¤© ANORO ELLIPTA ¤§«á¡A¥i©ó 14 ¤Ñ¤º¹F¨ìéwª¬ºA¡A¥B»W¿n¶q³Ì°ª¬° 1.7 ¿¡C ¤À§G¡G Umeclidinium¡G¹ï°·±d¨ü¸ÕªÌÀR¯ßª`®gµ¹ÃĤ§«á¡A¥§¡¤À§GÅé¿n¬° 86¤É¡CÅé¥~¸ÕÅçÅã¥Ü¡A¦b¤HÃþ¦å¼ß¤¤ªº¦å¼ß³J¥Õµ²¦X²v¥§¡¬°89%¡C Vilanterol¡G¹ï°·±d¨ü¸ÕªÌÀR¯ßª`®gµ¹ÃĤ§«á¡Aéwª¬ºA¤Uªº¥§¡¤À§GÅé¿n¬°165¤É¡CÅé¥~¸ÕÅçÅã¥Ü¡A¦b¤HÃþ¦å¼ß¤¤ªº¦å¼ß³J¥Õµ²¦X²v¥§¡¬° 94%¡C ¥NÁ¡G Umeclidinium ªº¥Dn¥NÁ³~®|¬°¥ý¸g®ñ¤Æ§@¥Î(ßm¤Æ§@¥Î¡BO-²æÖJ°ò§@¥Î)¡A¦A¸gµ²¦X§@¥Î(¦p¸²µå¿}îǻĤƧ@¥Î)¡A³Ì«á§Î¦¨¤@¨t¦CÃIJz¬¡©Ê°§C©ÎÃIJz¬¡©Ê©|¥¼½T¥ßªº¥NÁª«¡C vilanterol ¥Dn¬O³z¹L CYP3A4 ªº§@¥Î¶i¦æ¥NÁ¡A¨Ã¥B¬O P-gp Âà¹BÅ骺§@¥Î¨ü½è¡CVilanterol ·|¥NÁ¦¨¤@¨t¦CƒÒ1»PƒÒ2§@¥Î¬¡©Ê©úÅã°§Cªº¥NÁª«¡C ±Æ°£¡G Umeclidinium¡GÀR¯ßª`®g§ë¤©¸g©ñ®g¼Ð°Oªº umeclidinium ¤§«á¡A«í¶q¸ÕÅ窺µ²ªGÅã¥Ü¡A¦³ 58%ªº©ñ®g¼Ð°O¥X²{©óÁT«K¡A¨Ã¦³ 22%¥X²{©ó§¿²G¡C¥H¨C¤é¤@¦¸¤§¤è¦¡§ëÃī᪺¦³®Ä¥b°I´Á¬° 11 ¤p®É¡C ¤fªA§ë¤©¸g©ñ®g¼Ð°Oªº vilanterol ¤§«á¡A«í¶q¸ÕÅ窺µ²ªGÅã¥Ü¡A¦³ 70%ªº©ñ®g¼Ð°O¥X²{©ó§¿²G¡A¨Ã¦³ 30%¥X²{©óÁT«K¡C¦h¦¸§l¤Jµ¹Ãī᪺ÀË´úµ²ªGÅã¥Ü¡A vilanterol ªº¦³®Ä¥b°I´Á¬° 11 ¤p®É¡C
|
°Æ§@¥Î |
|
«|ª¢¡B»óÄuª¢¡B¤U©I§l¹D·P¬V¡B«K¯µ¡B¸¡Âm¡C
|
¥æ¤¬§@¥Î |
|
²ÓM¦â¯À P450 3A4 §í¨î¾¯ Vilanterol (ANORO ELLIPTA ªº¦¨¤À¤§¤@)¬° CYP3A4 ªº§@¥Î¨ü½è¡C»P±j®Äªº CYP3A4 §í¨î¾¯ ketoconazole ¦X¨Ö§ë¤©·|¤É°ª vilanterol ªº¥þ¨ÃnÃĶq¡C¦Ò¼{±N ANORO ELLIPTA »P ketoconazole ¤Î¨ä¥L¤wª¾ªº±j®Ä CYP3A4 §í¨î¾¯(¦p ritonavir¡B clarithromycin¡Bconivaptan¡Bindinavir¡Bitraconazole¡Blopinavir¡Bnefazodone¡Bnelfinavir¡B saquinavir¡Btelithromycin¡Btroleandomycin¡Bvoriconazole)¦X¨Ö§ë¤©®ÉÀ³ÂÔ·V¡C ³æÓi®ñ¤Æ酶§í¨î¾¯»P¤TÀô§Ü¼~Æ{¾¯ ©M¨ä¥Lªº£]2§@¥Î¾¯¤@¼Ë¡A¹ï¥¿¦b¨Ï¥Î³æÓi®ñ¤Æ酶§í¨î¾¯¡B¤TÀô§Ü¼~Æ{¾¯©Î¤wª¾·|©µªø QTc ¶¡´Á¤§ÃĪ«ªvÀøªº±wªÌ¡A©Î°±¥Î³oÃþÃĪ«¥¼¹F 2 ¶gªº±wªÌ¡A§ë¤© vilanterol ®ÉÀ³¯S§OÂÔ·V¡A¦]¬°³o¨ÇÃĪ«¥i¯à·|¼W±jµÇ¤W¸¢¯À§@¥Î¾¯¹ï¤ß¦åºÞ¨t²Îªº¼vÅT¡C¤wª¾·|©µªø QTc ¶¡´ÁªºÃĪ«¥»¨´N¦³¸û°ªªº¤Þµo¤ß«Ç©Ê¤ß«ß¤£¾ãªº·ÀI¡C
£]µÇ¤W¸¢¯À±µ¨üÅéªýÂ_¾¯
£]ªýÂ_¾¯¤£¶È·|ªýÂ_£]§@¥Î¾¯(¦p vilanterol¡AANORO ELLIPTA ªº¦¨¤À¤§¤@)ªºªÍ³¡§@¥Î¡A¤]¥i¯à·|«P¨Ï COPD ±wªÌµo¥ÍÄY«ªº¤ä®ðºÞµjÅË¡C¦]¦¹¡ACOPD ±wªÌ³q±`¤£¥i¨Ï¥Î£]ªýÂ_¾¯ªvÀø¡C¤£¹L¡A¦b¬Y¨Ç±¡ªp¤U¡A³o¨Ç±wªÌ°£¤F¨Ï¥ÎƒÒµÇ¤W¸¢¯ÀªýÂ_¾¯¤§¥~¡A¥i¯à¨S¦³¾A·íªº´À¥NÃĪ«¡F¥i¦Ò¼{¨ã¤ßŦ¿ï¾Ü©ÊªºƒÒªýÂ_¾¯¡A¦ý¨Ï¥Î³o¨ÇÃĪ«®É¤´À³ÂÔ·V¡C «D«O¹[§Q§¿¾¯ «D«O¹[§Q§¿¾¯(¦p loop Ãþ©Î thiazide Ãþ§Q§¿¾¯)©Ò¥i¯à³y¦¨ªº¤ß¹q¹ÏÅܤƤÎ/©Î§C¦å¹[²{¶H¥i¯à·|¦]ƒÒ§@¥Î¾¯(¦p vilanterol¡AANORO ELLIPTA ªº¦¨¤À¤§¤@)¦Ó¥X²{«æ©Ê´c¤Æªº²{¶H¡A¤×¨ä¬O¦b¶W¹L¸ÓƒÒ§@¥Î¾¯¤§«Øij¾¯¶qªº±¡ªp¤U¡CÁöµM¥Ø«e¨Ã¤£½Tª¾³o¨Ç¼vÅTªºÁ{§É·N¸q¡A¦ý¦b±N ANORO ELLIPTA »P«D«O¹[§Q§¿¾¯¦X¨Ö§ë¤©®É¤´À³ÂÔ·V¡C §ÜÁxÆP¿E©ÊÃĪ« »P§ÜÁxÆP¿E©ÊÃĪ«¨Ö¥Î¥i¯à·|²£¥Í¥[¦¨©Êªº¥æ¤¬§@¥Î¡C¦]¦¹¡AÀ³ÁקK±N ANORO ELLIPTA »P¨ä¥L§t¦³§ÜÁxÆP¿E©ÊÃĪ«¦¨¤ÀªºÃĪ«¨Ö¥Î¡A¦]¬°³o¼Ë¥i¯à·|¾ÉP§ÜÁxÆP¿E©Ê¤£¨}§@¥Î¼W¥[¡C
|
¸T§Ò |
|
¸T¥Î©ó¦³ÄY«¨Å³J¥Õ¹L±Ó°ÝÃDªº±wªÌ¡A©Î¤wÃÒ¹ê¹ïumeclidinium¡Bvilanterol ©Î¥ô¦ó½á§Î¾¯¹L±Óªº±wªÌ¡C
|
ª`·N¨Æ¶µ |
|
ANORO ELLIPTA ªº¨Ï¥ÎÀW²v¤£¥i¶W¹L«Øij¨Ï¥ÎÀW²v¡A¨Ï¥Î¾¯¶q¤£¥i°ª©ó«Øij¾¯¶q¡A¤]¤£¥i»P¨ä¥L§t¦³ LABA ¦¨¤ÀªºÃĪ«¨Ö¥Î¡A¦]¬°¥i¯à·|¾ÉP¥ÎÃĹL¶q¡C
|
ĵ»y |
|
1. ANORO ELLIPTA ¥Î©ó®ð³Ý±wªÌªº¦w¥þ©Ê»PÀø®Ä©|¥¼½T¥ß¡C 2. ANORO ELLIPTA¨Ã¤£¾A¥Î©óªvÀø®ð³Ý¡C
|
¹L¶q³B²z |
|
¥ÎÃĹL¶q®Éªº³B¸m¤è¦¡¥]¬A°±¥Î ANORO ELLIPTA¡A¦P®É¶}©l¶i¦æ¾A·íªº¯gª¬ªvÀø¤Î/©Î¤ä«ù©ÊªvÀø¡C©Î¥i¦Ò¼{¾A®É¨Ï¥Î¤ßŦ¿ï¾Ü©Ê±µ¨üÅéªýÂ_¾¯¡A¦ýÀ³ÂÔ°O¡A³oÃþÃĪ«¥i¯à·|¤Þµo¤ä®ðºÞµjÅË¡C«Øij¹ï¥ÎÃĹL¶qªº¯f¨Ò¶i¦æ¤ßŦºÊµø¡C
|
ÃÄ«~«O¦s¤è¦¡ |
|
1. ¦ÛÃIJ°¤¤¨ú¥X¤§«á¡A¥»«~³Ì¤[¥i¦s©ñ 6 ¶g¡C 2. ¤Á¤Å¦s©ñ©ó¶W¹L 30¢XC ªºÀô¹Ò¡C
|